By registering with us, you'll be able to discuss, share and private message with other members of our community.

  1. Welcome to the 12ozProphet Forum...
    You are currently logged out and viewing our forum as a guest which only allows limited access to our discussions, photos and other forum features. If you are a 12ozProphet Member please login to get the full experience.

    If you are not a 12ozProphet Member, please take a moment to register to gain full access to our website and all of its features. As a 12ozProphet Member you will be able to post comments, start discussions, communicate privately with other members and access members-only content. Registration is fast, simple and free, so join today and be a part of the largest and longest running Graffiti, Art, Style & Culture forum online.

    Please note, if you are a 12ozProphet Member and are locked out of your account, you can recover your account using the 'lost password' link in the login form. If you no longer have access to the email you registered with, please email us at [email protected] and we'll help you recover your account. Welcome to the 12ozProphet Forum (and don't forget to follow @12ozprophet in Instagram)!


Discussion in 'Channel Zero' started by qwertyuiop, Feb 15, 2002.

  1. qwertyuiop

    qwertyuiop Member

    Joined: Apr 16, 2001 Messages: 500 Likes Received: 0
    well, so much for not being depressed. my life sucks. im nowhere near getting laid, i have no friends, i have zits and braces, i dont fit in because im not one particular race, i havent been to a party since the eighth grade. ugh. feel sorry for me.
  2. qwertyuiop

    qwertyuiop Member

    Joined: Apr 16, 2001 Messages: 500 Likes Received: 0
    oh, i forgot one, im at home on a saturday night typing on an internet message board instead of doing something cool.
  3. Ski Mask

    Ski Mask 12oz Loyalist

    Joined: Apr 11, 2000 Messages: 11,114 Likes Received: 209
    on the bright side you have the ability to speak to us from the future. Anything happening tommorow I can win money on? help a brother out....
  4. idonotlikeu

    idonotlikeu Senior Member

    Joined: Nov 1, 2001 Messages: 1,874 Likes Received: 0
  5. iCEBERG

    iCEBERG Senior Member

    Joined: Oct 22, 2001 Messages: 2,039 Likes Received: 0
    ahhhhhhh.... hahahaha
  6. Smart

    Smart Dirty Dozen Crew

    Joined: Apr 14, 2000 Messages: 17,017 Likes Received: 177
    hahah, word Ese!
  7. ASER1NE

    ASER1NE Veteran Member

    Joined: Oct 15, 2001 Messages: 7,578 Likes Received: 3
  8. ASER1NE

    ASER1NE Veteran Member

    Joined: Oct 15, 2001 Messages: 7,578 Likes Received: 3
    aww crap , my plans fell through...........i guess my "saturday" is gonna be a boring one too.......


    well, if it makes you feel any better...im pretty cool and popular. and i chose to be on here too.:D
  10. me IS cool

    me IS cool Guest

    Am I pretty yet?
  11. Dr. Dazzle

    Dr. Dazzle Veteran Member

    Joined: Nov 19, 2001 Messages: 8,147 Likes Received: 3
    I'm on here because, well......uh, I don't know really
  12. ASER1NE

    ASER1NE Veteran Member

    Joined: Oct 15, 2001 Messages: 7,578 Likes Received: 3
  13. Dr. Dazzle

    Dr. Dazzle Veteran Member

    Joined: Nov 19, 2001 Messages: 8,147 Likes Received: 3
    Well, I think it's time for ol' Helacious D to hit the sack. Goodnight, sleep tight, everybody. Everybody, everywhere.......:dazed:
  14. ASER1NE

    ASER1NE Veteran Member

    Joined: Oct 15, 2001 Messages: 7,578 Likes Received: 3
    We are using our platform to discover disease-associated proteins, and to date, we have filed patent applications relating to, or to the use of, several thousand proteins associated with important diseases. We are using these proteins to build a pipeline of proprietary drug candidates and proprietary diagnostic products. We expect our drug candidates to include small molecule compounds discovered through our glycochemistry expertise and fully human therapeutic monoclonal antibodies developed through our alliance with Medarex. Over the next three years, we intend to contribute to our Medarex alliance up to 30 disease-associated proteins that antibodies target, called antigens. Our goal is to submit our first investigational new drug, or IND, filing from this alliance within 12 months and multiple INDs each year thereafter. We expect our diagnostic products to be based on our discovery of proteins that can be used to assess and monitor disease, which are generally referred to as bio-markers.

    In addition to our proteomics platform, we have extensive expertise in the field of carbohydrate biology known as glycobiology. This provides us with an additional source of protein targets for discovering drug candidates to treat such diseases as cancer, infectious disease, and glycolipid storage diseases. Our most advanced drug candidate, OGT 918, is a small molecule for the oral treatment of Gaucher's disease. OGT 918 is currently undergoing human clinical trials. Twelve-month trial data demonstrated statistically significant results in the primary objectives, or end-points, of reducing liver and spleen volume, as well as in the end-point of increasing platelets. Eighteen-month data on 18 patients that continued into an optional extension of the original trial, when compared with their data on entry into the trial, showed statistically significant reductions in liver and spleen volume, as well as statistically significant improvements in hemoglobin and platelets. OGT 918 has received 'fast track' designation by the U.S. FDA. We plan to file a new drug application, or NDA, for OGT 918 in 2001, subject to the successful completion of our preclinical and clinical development activities. We intend to develop a direct sales and marketing force to commercialise OGT 918 in some markets.

    We were originally founded around a core glycobiology platform and have become a leader in the field of human glycobiology. Glycobiology is the study of the structure and functions of carbohydrates, the processes by which carbohydrates are formed and destroyed in the human body, and the biological processes in which they participate.

    Our glycobiology background has given us an understanding of the processes in which carbohydrates are involved in human biology. We believe that the protein enzymes involved in the construction and break-down of carbohydrates (carbohydrate-processing enzymes, or CPEs) are an important class of targets for the discovery of new drugs for indications such as cancer, infectious disease and inflammation, as well as glycolipid storage diseases, such as Gaucher's disease, for which we are developing our leading product candidate, OGT 918. We have therefore continued to develop technologies for the analysis of carbohydrate structures, the isolation and cloning of CPEs, the design and implementation of highly selective high throughput screens for CPEs, and especially glycochemistry (the chemistries required to design carbohydrate analogs using combinatorial and medicinal chemistries).

    We have focused our internal small-molecule drug discovery efforts against selected CPEs, for which we have established and conducted high throughput screens, using our internally designed, built and assembled chemical libraries. These screens have been successful in yielding inhibitors that are being developed into product candidates by our team of chemists.